Trans-aTTom: Breast Cancer Index for prediction of endocrine benefit and late distant recurrence (DR) in patients with HR+ breast cancer treated in the adjuvant tamoxifen—To offer more? (aTTom) trial.

John M. S. Bartlett,Dennis C. Sgroi,Kai Treuner,Yi Zhang,Tammy Piper,Ranelle C. Salunga,Ikhlaaq Ahmed,Kristen M. Basnet,Elena F. Brachtel,Sarah Pirrie,Catherine A. Schnabel,Daniel Rea

Trans-aTTom: Breast Cancer Index for prediction of endocrine benefit and late distant recurrence (DR) in patients with HR+ breast cancer treated in the adjuvant tamoxifen—To offer more? (aTTom) trial.

2019

John M. S. Bartlett
Dennis C. Sgroi
Kai Treuner
Yi Zhang
Tammy Piper
Ranelle C. Salunga
Ikhlaaq Ahmed
Kristen M. Basnet
Elena F. Brachtel
Sarah Pirrie
Catherine A. Schnabel
Daniel Rea

505Background: The aTTom study is a prospective phase III trial that randomized 6953 HR+ women to stop or continue tamoxifen (TAM) for 5 more years after completing at least 4 years of prior TAM. R...

Keywords:

Breast cancer
Adjuvant
Tamoxifen
Endocrine system
Oncology
Pathology
Internal medicine
Medicine
distant recurrence
in patient
adjuvant tamoxifen

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations